After a previous ‘minded no’ with a request for further evidence, NICE has recommended rivaroxaban (Xarelto, Bayer Healthcare) as an option for treating deep vein thrombosis and preventing recurrent deep vein thrombosis and pulmonary embolism in adults diagnosed with acute deep vein thrombosis (DVT). This and the spate of other minded no’s was previously reported in the HEDS Blog.
The Evidence Rview Group were ScHARR-TAG, with Sue Harnan, Rachid Rafia, Edith Poku, John Stevens, Matt Stevenson and Ruth Wong doing the work. As well as undertaking the original appraisal, the group produced a 28 page examination of the additional evidence provided by the manufacturer, which is available here.
